Laropiprant er ikke et substrat af humant P- gp, og derfor forventes andre hæmmere af CYP3A4 og/ eller P- gp heller ikke at have en klinisk relevant indvirkning på laropiprants farmakokinetik.
Laropiprant is not a substrate of human P-gp, and therefore other inhibitors of CYP3A4 and/ or P-gp are also not expected to have a clinically meaningful impact on the pharmacokinetics of laropiprant.